1. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma
   Luiza Lara Gadotti et al, 2021, Clinical Lung Cancer CrossRef
2. Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
   Liping Lin et al, 2017, Oncotarget CrossRef
3. Évaluation, prévention et gestion des toxicités des inhibiteurs d’ALK et d’EGFR
   B. Mennecier et al, 2018, Revue des Maladies Respiratoires Actualités CrossRef
4. Pneumopathie infiltrative diffuse, péricardite et pleurésie d’hypersensibilité compliquant un traitement par ceritinib
   C.-M. Gaillard et al, 2019, Revue des Maladies Respiratoires CrossRef
5. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease
   Jhong-Ru Huang et al, 2021, Journal of Oncology Pharmacy Practice CrossRef